Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Toray Industries, Inc
Mayo Clinic
Eli Lilly and Company
Seagen Inc.
Eli Lilly and Company
Washington University School of Medicine
Northwestern University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)